With the Cardiac Reader reliable quantitative results can be easily obtained for both cardiac markers. The system is, therefore, particularly suitable for use in emergency rooms, coronary care units and small hospitals.
Introduction
The value of the determination of cardiac troponin T (cTnT) for diagnosis, risk stratification and therapeutic and clinical decision-making in patients with acute coronary syndromes has been demonstrated in many retrospective and prospective studies (1) (2) (3) . Due to its high early sensitivity, myoglobin complements measurement of troponinT with the ability for exclusion diagnosis of acute myocardial infarction (4) (5) (6) (7) (8) (9) (10) , the diagnosis of reinfarction (11) and assessment of reperfusion in thrombolysis (12) (13) (14) (15) (16) (17) (18) .
Since its introduction in 1994, a rapid bedside test allows quick and simple qualitative determination of cTnT. Over three generations of the test, the detection limit has improved from the original 0.3µg/l (19) (20) (21) to 0.2µg/l in the second generation (22, 23) and finally to 0.1µg/l in the third (24, 25) . At the same time, cross-reactivity with skeletal troponinT (sTnT) has been eliminated by replacement of one of the antibodies (25) . Comparative studies have shown this test to be sufficiently robust to be used by clinic staff outside a laboratory environment, delivering results of comparable analytical quality (25, 26) .
Similarly, there is a rapid qualitative test for early determinations of myoglobin (27) .
However, purely qualitative determinations of troponinT and myoglobin limit their range of applications. In the case of troponin T, although triage is possible on the basis of qualitative results alone, a quantitative prognostic assessment of cardiac risk (28) (29) (30) or a decision for a certain therapy can only be made if the exact troponinT concentration is known (31, 32, Ohman, personal communication) . For myoglobin, a quantitative value is almost indispensable, since it is only through an evaluation of its release kinetics that a reliable infarct diagnosis can be made (5, 8-10, 33, 34) . Release kinetics are also required for assessment of reperfusion.
We have therefore developed a system, based on the existing troponinT rapid test, that permits a quantitative determination of troponin T. A completely new quantitative myoglobin test was also developed for this system. We describe the operating principle of this new system for rapid determination of troponinT and myoglobin in heparinized blood and present the results of a multicenter evaluation.
Materials and Methods

Test principle of the Cardiac Reader
The Cardiac Reader (Roche Diagnostics, Mannheim, Germany) is a system for quantitative bedside determinations of myoglobin (CARDIACM) and troponinT (CARDIACT Quantitative). The chemical reaction principle of the test strips has been described previously (20, 21) . The Cardiac Reader is a camera with a charged coupled device that optically records the reflectance signal from the detection zone of the immunochemical test strips (Figure1). Signal and control lines are identified by a pattern recognition algorithm. The intensity of the signal line is proportional to the concentration of the analytes troponin T and myoglobin. The optical signal is converted into concentration via a lot-specific calibration curve (see below), which is stored in a code chip.
The tests require a 150µl sample of heparinized blood and the reaction times are approximately 8min for myoglobin and approximately 12min for troponinT determination.
For CARDIACT Quantitative the quantitative measurement range is 0.1 to 3µg/l troponin T; the display shows values below 0.05µg/l as "negative", values between 0.05 and 0.1µg/l as "low", and values above 3.0µg/l as "high". For CARDIAC M, the quantitative measurement range is from 30 to 700µg/l myoglobin; values below this range are displayed as "negative" and values above as "high".
Calibration of the Cardiac Reader
CARDIACM was calibrated identically as CARDIACT Quantitative. Parallel samples of heparinized blood and serum were collected from over a hundred patients with suspected acute coronary syndromes. Heparinized blood samples were used to determine the reflectance with CARDIACM, and serum samples to measure the myoglobin concentration with Tinaquant Myoglobin (Roche Diagnostics) 1 . The resulting pairs of values were used to calibrate this lot of CARDIACM by regression analysis. This lot served as a master lot for calibrating further lots. Using this master lot, and a new lot to be calibrated, measurements were taken on 18blood samples spiked with various concentrations of myoglobin. The concentrations obtained with the master lot served as target concentrations for the new lot; the corresponding reflectance values were obtained directly from measurements. The resulting pairs of values (target concentration/reflectance) were then used to establish the calibration curve for the new lot of CARDIACM.
The lot-specific calibration curve is communicated to the reader via a code chip. The agreement of code and test strip is checked by the bar code ( Figure 1 ) on the bottom of the test strip.
Imprecision and between-instrument variability
Investigations of within-series imprecision and of inter-instrument variability were carried out on heparinized blood samples collected from healthy volunteers and spiked with troponin T-containing sera or purified myoglobin and with control material (controls of the Cardiac Reader system and calibrators of the reference methods). Hematocrit of all spiked samples was readjusted to the initial value of the original donor blood sample. Each sample was measured 10times at 20different instruments using one lot. For each series (n = 10) at each instrument, mean value and coefficient of variation (CV) were calculated. The CVs for the within-series imprecision given in the result section were calculated as mean values of the 20 CVs with 20 instruments. The between-instrument CVs were calculated as the CVs of the serial mean values from 20 instruments. Serial measurements were done by one laboratory technician.
Method comparisons
Method comparisons were done at seven centers using altogether 281 sets of heparinized blood and serum samples collected in parallel from unselected patients with suspected acute coronary syndromes. Patients with recent cardiac surgery or other type of interventional therapy, patients with renal and/or skeletal disease or injury were not excluded. Multiple specimen collection per patient was possible. We compared CARDIAC T Quantitative (lot 226003) with cTnT ELISA (Enzymun-Test Tr op o n i n T, Roche Diagnostics) 1 on multiple ES300 instruments (Roche Diagnostics) in accordance with the manufacturer's instructions, using a cut-off value of 0.1 µg/l (35) .
We compared CARDIACM (lot226012-20) with Tina-quant Myoglobin (Roche Diagnostics) on multiple Hitachi instruments (Roche Diagnostics). The reference range is <69µg/l (36) and a cut-off of 70µg/l was used in the evaluations.
Lot numbers in use for troponin T on the ES 300 analyzer and myoglobin on the Hitachi were the same for all seven centers contributing to the multicenter study.
Daily quality control
The quality control of CARDIAC T Quantitative and CARDIAC M comprised a daily single determination of both CARDIAC control troponin T level 1 and 2 or both CARDIAC control myo-1 Tina-quant and Enzymun-Test are trademarks of a member of the Roche group. globin level 1 and 2 (Roche Diagnostics), respectively, at each center. The quality control of cTnT ELISA and Tina-quant myoglobinwas performed at each center with the respective package controls.
Lot-to-lot comparison
To check the reproducibility of the calibration, five lots of CAR-DIACM (226007, 226008, 226009, 2260012-20, 2260012-30) and six lots of CARDIACT Quantitative (226003, 226005, 226013, 226014, 226026, 226031) were investigated using fresh heparinized blood collected from patients with suspected acute coronary syndromes. The numbers of samples are listed in Table1.
Interference studies
To check for interfering factors, heparinized blood or plasma was spiked with potential interfering substances (sTnT), biotin, hemoglobin, bilirubin, 18standard drugs) from a stock solution (for final concentrations see Table2; for concentrations of the drugs see Table 3 and ref. 37 ) and with a human serum sample containing troponinT in a high concentration. The influence of triglycerides was investigated using human lipemic serum samples spiked with troponinT sera. To determine the influence of hematocrit, samples collected from patients with coronary artery disease were used. Volume dependence was investigated using heparinized blood samples from healthy donors spiked with a human serum sample containing troponinT in a high concentration.
Cross-reactivity of CARDIACT Quantitative with sTnT was calculated according to the following formula:
Comparisons of recoveries in the hematocrit study were performed by a h-test according to Kruskal-Wallis with a level of significance of p < 0.05. 
Results
Within-series imprecision
The within-series CV (Figure 2 ) was 5 to 10% for CAR-DIACM and 10 to 15% for CARDIACT Quantitative. This imprecision is observed both with blood and with control materials and is fairly constant regardless of the concentration of the analyte.
Between-instrument variability
The between-instrument CV for CARDIACM was 5 to 10% in the concentration range below 100 µg/l and 2 to 3% in the range above 100 µg/l. For CARDIAC T Quantitative the between-instrument CV was 4 to 9% ( Figure 3) .
Accuracy in the method comparison
Both Cardiac Reader methods were in good agreement with the laboratory methods. Figure 4 shows the combined method comparison of all centers between CARDIACM and Tina-quant Myoglobin. This shows that CARDIACM was calibrated correctly, as the results obtained are 8% lower relative to the reference and calibration method when the whole test range is regarded. 
Daily quality control
The results of the daily quality control are listed in Ta b l e 4. With CARDIAC M and CARDIAC T Quantitative, slightly poorer recovery and imprecision were observed from "day-to-day" than "within" series, which may be attributable to daily variations in reconstitution of the controls. The values obtained with the reference methods show the variation to be within the target ranges.
Lot-to-lot variability
In lot-to-lot comparisons, the lots of CARDIACT Quantitative investigated showed good agreement with one another, as did the lots of CARDIACM (Table1). For CARDIACT Quantitative, the correlation coefficients r were between 0.92 and 0.97 and the accuracy differences were between -6% and +5%. CARDIAC M showed correlation coefficients between 0.97 and 0.99 with accuracy differences ranging from 0% to +11%.
Interference
In investigations with biotin (up to 100 µg/l), hemoglobin (up to 2000 mg/l), bilirubin (up to 200 mg/l), and The same analysis for CARDIACT Quantitative with the cTnTELISA reference method showed a bias of 7% for the whole test range ( Figure 5 ).
When the results obtained with CARDIACT Quantitative were compared with the reference method cTnT triglycerides (up to 5000 mg/l), no significant analytical interference was detected, i.e. all deviations from expected values were ≤ 10%. Overdosing or underdosing by 15µl affected the test result by no more than 10% (Table2).
Appreciable cross-reactivity with sTnT was only observed at concentrations from 1000µg/l. Cross-reactivity was, therefore, calculated to be approximately 0.003% (Table2).
Various standard drugs did not influence the recovery with CARDIACT Quantitative and CARDIACM by more than 26% when toxic concentrations of the drugs were used, and by no more than 12% when therapeutic concentrations were used (Table 3) .
No significant correlation was found between hematocrit and the recovery of the reference method concentrations by the Cardiac Reader tests (CARDIAC T Quantitative: r = 0.12, CARDIACM: r = -0.05). The slightly lower recovery with CARDIAC M at higher hematocrits is not significant (p > 0.05) in the h-test according to Kruskal-Wallis (Table 5) .
Discussion
Newer cardiac markers like the troponins have contributed substantially to the diagnostic workup of patients with suspected myocardial infarction. Risk stratification of patients with unstable angina and suspected minor myocardial damage is possible with a marker such as troponin T rather than simple ruling in or out of myocardial infarction based on classic WHO criteria.
A crucial point for the clinical utility of a marker is the time from the first investigation of the patient and blood sampling until the time a result is available which is then used for clinical and therapeutic decisionmaking by the physician. In this setting, point-of-care systems will offer a more rapid result.
It is now possible to test highly specific troponin T and the early marker myoglobin quantitatively with a turnaround time of less than 15 minutes at the bedside.
No significant analytical interference was found when various standard drugs, triglycerides, bilirubin and biotin were tested. Underdosing or overdosing a blood sample by 15 µl (standard volume 150 µl) influenced the test result by no more than 10%. The crossreactivity with skeletal troponin T was calculated to be approximately 0.003%. No significant correlation was found between the hematocrit and the concentrationdependent recovery with both quantitative bedside assays.
Addition of all the errors (imprecision, lot-to-lot variability, accuracy in the method comparison) yielded a total error range of ±25% for CARDIACT Quantitative and ±30% for CARDIACM. The variation of a test result is of most importance in the range near the cut-off level. At the cut-off for troponinT (0.1µg/l), CARDIAC T Quantitative, therefore, has a maximum range of variation between 0.075 and 0.125µg/l, after taking into account the differences between lots and the comparison with the reference method. At the cut-off for myoglobin (70µg/l), CARDIACM has a calculated maximum range of variation from 49 to 91µg/l. However, in serial measurements with CARDIACM, which is the primary need for a quantitative myoglobin value, only imprecision remains as a source of variation, so that the total error range diminished to ±15% (59 to 81µg/l at the cut-off).
When using the clinical cut-off of 0.1 µg/l, there were only 1% discordant results between CARDIACT Quantitative and the reference method cTnT ELISA. Comparing the two myoglobin tests with the cut-off level of 70 µg/l, we found 6% discordant results. These discrepancies of 1% with troponin T and 6% with myoglobin are probably caused by imprecision of both the tested method and the reference method.
The Cardiac Reader was designed to allow a rapid Tab. 4 Summary of the results of the daily quality control in the multicenter evaluation. The medians for different hematocrit ranges are shown.
point-of-care determination of two essential cardiac markers. The clinical performance of the quantitative bedside assays for troponin T and myoglobin is being further investigated in clinical studies ongoing at present. Preliminary results from these studies show the gain in time by using the Cardiac Reader compared to conventional laboratory testing (72 minutes, p < 0.0001) (Collinson, unpublished data) . The design of the Cardiac Reader meets the requirements on the use of cardiac markers in point-of-care testing as recommended by two scientific societies. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Guidelines on biochemical markers in coronary artery disease (39) , which are in line with the National Academy of Clinical Biochemistry (NACB) Guidelines (40), recommend the routine use of cardiac troponins in acute coronary syndromes. The value of myoglobin as an early marker of cardiac damage has been acknowledged in the IFCC Guidelines on cardiac markers as well as in the NACB Guidelines. The importance of point-of-care testing has been emphasized both in the IFCC Guidelines and the NACB Guidelines. Moreover the NACB Guidelines recommend a turnaround time of one hour or less for biochemical testing.
Conclusions
The Cardiac Reader represents an analytically reliable and easy method that further extends the spectrum of applications of the visual troponin T rapid assay test in early infarct diagnostics, in reperfusion control, and in cardiac risk assessment. With these attributes, it is, therefore, suited for adoption by emergency departments, coronary care units and small hospitals with few cardiac patients where investment in larger and more expensive equipment is not justified.
